Klotho-derived peptides
Short fragments of the anti-aging protein Klotho engineered to reproduce its cognitive and kidney-protective effects in a molecule small enough to actually manufacture and dose.
Also known as KL1 domain peptides, alpha-Klotho fragments, soluble Klotho mimetics
Animal data only — Rodent or other animal studies. Dose translation to humans is genuinely uncertain.
Excellent mouse genetics establishing Klotho as a genuine longevity gene, plus a striking single-dose cognitive result in aged rhesus macaques. Everything about the peptide fragments specifically is preclinical or theoretical — no validated fragment sequence, no human data, no clinical programme with published results as of mid-2026.
How it works
Alpha-Klotho is a single-pass transmembrane protein whose extracellular domain, comprising the KL1 and KL2 subdomains, is shed into blood, urine and cerebrospinal fluid as soluble Klotho. It acts partly as an obligate co-receptor for FGF23 and partly as an independent circulating factor that inhibits insulin/IGF-1 signalling, antagonises Wnt and TGF-beta, modulates ion channels including TRPV5 and ROMK by deglycosylation, and scavenges reactive oxygen species. Klotho-deficient mice show accelerated aging with vascular calcification, sarcopenia and cognitive decline; overexpression extends lifespan. The headline result driving the field is that a single low peripheral dose of soluble Klotho improved cognition in aged rhesus monkeys, with benefits appearing days after a dose that barely raised circulating levels — implying an indirect signalling mechanism rather than direct CNS exposure, since intact Klotho does not meaningfully cross the blood-brain barrier. That is precisely why fragments are attractive: the parent protein is a heavily glycosylated 130 kDa protein that is expensive to make and cannot reach the brain. Whether a KL1-derived peptide retains the relevant activity is still unresolved.
Targets: FGF23/FGFR co-receptor complex, Insulin/IGF-1 signalling, Wnt signalling, TGF-beta receptor 2, TRPV5 and ROMK channels
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| No human protocol existsNot applicable. | — | not established | subcutaneous |
- · The primate work used a single low subcutaneous dose of full-length soluble Klotho scaled to body weight. No Klotho-derived peptide has been given to a human in a published study, and no fragment sequence has been validated as reproducing the parent protein's effects. Material sold as 'Klotho peptide' has no defined identity.
Cycling
Not established. Notably, the primate data suggest low doses outperformed high doses, so more is explicitly not better here.
Pharmacology
- Half-life
- Not established for any fragment. Full-length soluble Klotho clears within hours in primates, yet the cognitive effect persisted for days, which is itself an unexplained finding.
- Onset
- Cognitive effects in the primate study appeared within about four hours and persisted for at least two weeks after a single dose.
- Routes
- subcutaneous, intravenous
- Molecule
- Engineered peptide fragments derived from the KL1 and KL2 domains of alpha-Klotho
Handling
- Diluent
- Bacteriostatic water
- Lyophilised
- Freezer at -20 C or below.
- Reconstituted
- Refrigerated, short term; avoid freeze-thaw.
Mixing
Full-length Klotho is a glycoprotein requiring mammalian expression. Anything cheap enough to buy as a research peptide is a fragment of unproven activity at best.
Side effects
- commonUnknown in humans— No published human administration of Klotho or any fragment.
- uncommonPhosphate and calcium dysregulation— Theoretical but mechanistically grounded — Klotho is central to FGF23-mediated phosphate handling and to renal calcium reabsorption via TRPV5.
Do not use if
- Chronic kidney disease with disordered mineral metabolism - interfering with the FGF23-Klotho axis in this population could plausibly worsen phosphate and calcium handling.
- Human use outside research generally.
What to monitor
- · If it ever reaches humans: serum phosphate, calcium, PTH and FGF23 would be the first-order safety panel.
Legal status
Research reagent. No approved product; no legitimate consumer supply.
References
- Kuro-o et al. 1997, Nature — mutation of the mouse klotho gene leads to a syndrome resembling ageing (preclinical)
- Castner et al. 2023, Nature Aging — longevity factor klotho enhances cognition in aged nonhuman primates (preclinical)
Mechanism in depth
Klotho is a transmembrane protein whose soluble ectodomain acts as a co-receptor for FGF23 and, independently, as a circulating factor implicated in ageing, cognition and renal protection. Klotho-derived peptides attempt to reproduce fragments of that activity in a small, synthesisable molecule. The parent biology is strong - klotho-deficient mice show accelerated ageing phenotypes - but the leap from that to a short peptide fragment is large.
What usually goes wrong
The evidence for klotho the protein is being transferred wholesale onto peptides derived from it, which is not how fragment pharmacology works - a fragment retains the activity it retains, and that has to be demonstrated for each one. Full-length klotho is a large glycoprotein and its co-receptor function depends on structure a short peptide does not have.
Receptor targets
- FGF receptor complexes; additional targets proposed — Not characterised for the derived fragments
Proposed renal, vascular and cognitive protection
Genuinely uncertain
- Whether any short klotho-derived fragment reproduces the protein's function is unestablished.
- No human trial of a klotho-derived peptide has been completed.
- Products sold under this name have no published identity or purity verification.